These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 20661668)

  • 1. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    de Castria TB; da Silva EM; Gois AF; Riera R
    Cochrane Database Syst Rev; 2013 Aug; (8):CD009256. PubMed ID: 23949842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
    Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S
    Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
    Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M
    Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
    Tada H; Matsui S; Kawahara M; Hosoe S; Hamada C; Fukushima M
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):120-6. PubMed ID: 18302648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
    Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
    Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A; Liptay M; LaCombe M; Marymont M; Kies MS; Sundaresan S; Masters G
    Lung Cancer; 2004 Aug; 45(2):243-53. PubMed ID: 15246197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.
    Rosati G; Rossi A; Nicolella G; Panza N
    Anticancer Res; 2000; 20(3B):2229-33. PubMed ID: 10928183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
    Laack E; Mende T; Dürk H; Kneba M; Dickgreber N; Welte T; Müller T; Scholtze J; Graeven U; Jasiewicz Y; Edler L; Hossfeld DK
    Eur J Cancer; 2002 Mar; 38(5):654-60. PubMed ID: 11916547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
    Pérol M; Léna H; Thomas P; Robinet G; Fournel P; Coste E; Belleguic C; Le Caer H; Blanchon F; Vergnenègre A; Vernejoux JM; Schuller-Lebeau MP; Pham E
    Ann Oncol; 2002 May; 13(5):742-7. PubMed ID: 12075743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.